Q4 & FULL YEAR 2020 FINANCIAL RESULTS

February 23, 2021

ESPERION The Lipid Management Company

SAFE HARBOR

FORWARD- LOOKING STATEMENTS

This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the global clinical development and commercialization plans for bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet, including ESPERION's timing, designs, plans for announcement of results regarding its CLEAR Outcomes study and other ongoing clinical studies for bempedoic acid tablet and the bempedoic acid / ezetimibe combination fixed dose tablet, timing for the review and approval of expanded indications for their effect on cardiovascular events, ESPERION's expectations for the market for medicines to lower LDL-C, including the prospects for success of the commercial launch and market adoption of bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet in the United States and European Union, the development of ESPERION's in-licensed pre-clinical oral PCSK9 inhibitor program, and ESPERION's financial outlook, including expectations for future revenues from its product sales, partnership collaborations and other sources. Any express or implied statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause ESPERION's actual results to differ significantly from those projected, including, without limitation, delays or failures in ESPERION's clinical development and commercialization plans, or approval of expanded indications, that existing cash resources may be used more quickly than anticipated, that Otsuka and DSE are able to successfully commercialize its products, the impact of COVID-19 on our business, clinical activities, supply chain, commercial development and launch plans, and the risks detailed in ESPERION's filings with the Securities and Exchange Commission. Any forward-looking statements contained in this presentation speak only as of the date hereof, and ESPERION disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this presentation other than to the extent required by law.

BUSINESS HIGHLIGHTS

Tim M. Mayleben, President & CEO

ESPERION The Lipid Management Company

EVERY PATIENT'S GOALS ARE UNIQUE

We are singularly focused on bad cholesterol

LIPID MANAGEMENT FOR EVERYBODY

35 Million

patients considered statin intolerant in the U.S., Japan and the EU. [1]

20%

of individuals who were treated with a statin are impacted by statin intolerance[2]

25%

increase in the deaths from Cardiovascular Disease by 2030 according to the CDC

[1]Datamonitor Healthcare's proprietary dyslipidemia survey, November 2016

[2]Bruckert E, Hayem G, Dejager S, Yau C and Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients

the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403-14


+25,000
PATIENTS
AND
CLIMBING
EVERYDAY
2020
Approvals & launches in key markets of U.S. & DE
Became commercial company
2021
Increasing patient need
Pandemic recovery
Enhanced execution
Europe broad launch
ROW partner announced
2022+
CVOT label expansion
Oral PCSK9 + pipeline
Japan, ROW launches

CLEAR OUTCOMES PROGRESSES UNINTERRUPTED BY PANDEMIC

Pioneering event-driven trial, the first of its kind, focusing on statin intolerant patients

+14,000 patients enrolled and powered for success and is optimally designed to demonstrate the full potential of bempedoic acid

Expect high baseline LDL-C (~140 mg/dL)

Long treatment duration (median 3.5yrs)

Statin intolerance impacts up to 20% of individuals who have been treated with a statin[1]

1 Bruckert E, Hayem G, Dejager S, Yau C and Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403-14.

OPERATIONS OVERVIEW

Sheldon Koenig, COO

ESPERION The Lipid Management Company

PROGRESS, DESPITE PANDEMIC

8,600+
Doctors writing at least one prescription

3,300+
Patients taking our medicines every week

420,000+
Seven-day starter packs have requested and received to begin patients on our medicines easily

IMPACTS FROM COVID-19 IN THERAPEUTIC AREA
New-to-brand statin prescriptions remain depressed – YTD 2021 down 9% compared to YTD 2020

OPERATIONAL EXCELLENCE INITIATIVES

DRIVE AWARENESS

- Leverage Medical Science Liaisons
- Establish Scientific Platform

EXPAND MEDICAL EDUCATION

- Enhance Product Positioning
- Real World Evidence Study
- Promote Health Economics Benefits

PULL THROUGH MANGED CARE

- Integrate Reimbursement Specialty

FINANCIAL UPDATE

Rick Bartram, CFO

ESPERION The Lipid Management Company

DIVERSIFIED REVENUE STREAMS PROGRESSING

Significant U.S. Net Product Revenue Growth; First Royalty Revenue Reported



U.S. Net Product Sales increased +146% quarter over quarter

Ex-U.S. Royalty Revenues

1st Royalty from DSE in Quarter

Ex-U.S. Collaboration Milestones

>$1 Billion

ESPERION

COST MANAGEMENT SUPPORTS OUR STRONG FINANCIAL POSITION

Key Financial Data	
FY Revenue	No Guidance Before 2022
FY 2021 R&D Guidance	$120 - $130 Million
FY 2021 SG&A Guidance	$200 - $210 Million
FY 2021 Op Ex Guidance(1)	$320 - $340 Million
FY 2020 Common Shares Outstanding(3)	25.9 Million
FY 2020 Cash Balance	$305 Million

[1] Includes $30M of non-cash stock based compensation expense
[2] Original guidance issued on February 27, 2020
[3] Accounts for $50M prepaid forward feature

ESPERION

MULTI-YEAR GROWTH OPPORTUNITY FOCUSED ON SIGNIFICANT PATIENT NEED FOR LIPID MANAGEMENT

Accelerating Launch

U.S.

Building Momentum

International

Expanding Innovation

Pipeline

Key Growth Drivers

- Pandemic recovery
- Enhanced execution
- CVOT label expansion
- European launch
- OUS partner milestones (>$1B)
- Oral PCSK9i program advancement

THANK YOU

ESPERION® The Lipid Management Company